Plasma cell leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:13 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Plasma cell leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of ARI0002h and Drug Combination for Newly Diagnosed Primary Plasma Cell Leukemia Patients https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ari0002h-and-drug-combination-for-newly-diagnosed-primary-plasma-cell-leukemia-patients/ Wed, 29 Apr 2026 15:04:01 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ari0002h-and-drug-combination-for-newly-diagnosed-primary-plasma-cell-leukemia-patients/ This clinical trial is focused on studying a type of blood cancer called primary plasma cell leukemia. The study is testing a new treatment called ARI0002h, also known as Cesnicabtagene autoleucel. This treatment involves using a patient’s own immune cells, which are genetically modified to better fight the cancer. These modified cells are called CAR-T cells, and they are designed to target a specific protein found on the cancer cells known as BCMA.

The purpose of the study is to evaluate the safety and effectiveness of this new treatment in patients who have been newly diagnosed with primary plasma cell leukemia. Participants in the study will receive the ARI0002h treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor how well the treatment works in reducing the cancer and will also look at any side effects that may occur. Some patients may receive additional medications such as Lenalidomide, Cyclophosphamide, Fludarabine, Paracetamol, or Tocilizumab to help manage symptoms or enhance the treatment’s effectiveness.

The study will take place over several months, with regular check-ups to assess the response to the treatment and monitor for any side effects. The goal is to see if the treatment can help control the disease and improve the quality of life for patients with primary plasma cell leukemia. Participants will be closely monitored for any reactions to the treatment, including potential side effects like cytokine release syndrome and neurological symptoms. The study aims to provide valuable information on the potential benefits and risks of using ARI0002h for this type of cancer.

]]> Study on the Effectiveness and Safety of Bortezomib and Daratumumab for Patients with Primary Plasma Cell Leukemia https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bortezomib-and-daratumumab-for-patients-with-primary-plasma-cell-leukemia/ Wed, 29 Apr 2026 15:02:27 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bortezomib-and-daratumumab-for-patients-with-primary-plasma-cell-leukemia/ This clinical trial is focused on studying a rare type of blood cancer called primary plasma cell leukemia. The study aims to evaluate the effectiveness and safety of a treatment plan that includes alternating regimens based on the drug bortezomib, combined with another medication called daratumumab. The treatment plan also includes a maintenance phase where only daratumumab is used. Bortezomib is administered as a powder for solution for injection, while daratumumab is given as a solution for injection. Other medications involved in the study include doxorubicin hydrochloride, dexamethasone sodium phosphate, and cyclophosphamide.

The purpose of the study is to assess how well this combination of treatments works in patients who have not received any prior treatment for their condition. The study will follow a specific course where patients will receive the alternating bortezomib-based regimens in combination with daratumumab, followed by a consolidation phase with daratumumab and other medications, and finally a maintenance phase with daratumumab alone. The study will monitor the patients over a period to see how long they remain free from disease progression.

Participants in the study will receive the medications through different methods, such as subcutaneous use (under the skin), intravenous use (into a vein), and oral use (by mouth). The study is designed to provide valuable information on the potential benefits and safety of this treatment approach for primary plasma cell leukemia, helping to improve future treatment options for this challenging condition.

]]> Study on Daratumumab, Lenalidomide, and Dexamethasone for Patients with Primary Plasma Cell Leukemia https://clinicaltrials.eu/trial/study-on-daratumumab-lenalidomide-and-dexamethasone-for-patients-with-primary-plasma-cell-leukemia/ Wed, 29 Apr 2026 14:58:10 +0000 https://clinicaltrials.eu/trial/study-on-daratumumab-lenalidomide-and-dexamethasone-for-patients-with-primary-plasma-cell-leukemia/ This clinical trial is focused on studying a rare type of blood cancer called Primary Plasma Cell Leukemia. The study involves a combination of treatments, including a medication called Darzalex (daratumumab), which is given as an injection, and Revlimid (lenalidomide), which is taken as capsules. Other medications used in the study include Dexamethasone, which can be administered either as an injection or an oral solution, and Bortezomib, which is given as an injection. The purpose of the study is to determine the best overall response rate after the initial treatment phase.

Participants in the study will receive these treatments over a period of time, with the aim of understanding how well the combination works in treating the disease. The study will also look at how long patients live without the disease getting worse, overall survival rates, and the duration of response to the treatment. Additionally, the study will assess the safety of the treatments by monitoring any side effects and changes in health indicators.

The study will also evaluate the response to treatment based on specific genetic changes in the cancer cells, such as del(17p) and t(4;14). Another aspect of the study is to assess the quality of life of participants using a questionnaire known as EORTC QLQ-C30. The study is expected to continue until 2028, providing valuable insights into the effectiveness and safety of the treatment combination for Primary Plasma Cell Leukemia.

]]>